MOTS-C vs MK-677: opposite effects on insulin sensitivity

MOTS-C and MK-677 are frequently discussed together, but they sit on opposite sides of the metabolic ledger.

MK-677 (ibutamoren) is an oral ghrelin mimetic that drives sustained, 24-hour GH elevation. That continuous GH exposure raises IGF-1 but reliably worsens insulin sensitivity, elevating fasting glucose and HbA1c in human trials. It is the most popular GH secretagogue in bodybuilding because it is oral, cheap, and increases appetite, but its metabolic cost is well-documented.

MOTS-C is a mitochondrial-derived peptide that activates AMPK, the same pathway recruited by exercise and metformin. In animal models it improves insulin sensitivity and lowers glucose through insulin-independent GLUT4 translocation. Its evidence base is far thinner than MK-677's: mouse efficacy plus human correlations, with no completed efficacy trial in healthy people.

The reason athletes compare them is the mirror-image metabolic effect. MK-677 adds insulin resistance; MOTS-C theoretically removes it. The temptation is to run them together, with MOTS-C offsetting MK-677's glucose cost. That logic is mechanistically clean but clinically unproven.

Direction of metabolic effect: This is the headline. MK-677 worsens insulin sensitivity (higher fasting glucose, higher HbA1c, higher HOMA-IR). MOTS-C, in animal models, improves it. They are metabolic opposites.

Mechanism: MK-677 works through the GH axis (sustained ghrelin-receptor stimulation driving continuous GH release). MOTS-C works through AMPK and the folate-AICAR pathway, independent of GH and insulin.

Evidence quality: MK-677 has multiple human RCTs, including a 12-month trial (Nass et al., 2008) quantifying its glucose and HbA1c effects. MOTS-C has mouse efficacy and human observational correlations only; the one completed interventional human trial used an engineered analog (CB4211), not native MOTS-C.

Effect on glucose markers: MK-677 at 25 mg/day raised fasting glucose roughly 5 mg/dL and HbA1c 0.2% over 12 months (Nass et al., 2008), and an earlier study saw glucose climb from 5.4 to 6.8 mmol/L in 4 weeks (Chapman et al., 1996). MOTS-C is expected, if anything, to nudge these down, but the human magnitude is unknown.

Route and convenience: MK-677 is a once-daily oral tablet. MOTS-C is a subcutaneous injection.

IGF-1 and anabolism: MK-677 raises IGF-1 substantially (equivalent to 2-3 IU of GH). MOTS-C does not raise IGF-1 and is not anabolic; its appeal is metabolic, not muscle-building.

Appetite: MK-677 strongly increases appetite. MOTS-C does not.

Regulatory and doping status: both are unapproved for this use. MOTS-C is explicitly named on the 2026 WADA Prohibited List as an AMPK activator (S4.4.1). MK-677 is also WADA-banned as a GH secretagogue.

Choose MK-677 if:

• Your goal is raising IGF-1 and GH for size, recovery, and sleep
• You want oral convenience and lower cost
• You are bulking and the appetite increase is welcome
• You have clean baseline metabolic markers and will monitor glucose, insulin, and HbA1c every 3 months
• You accept the documented insulin-resistance cost

Choose MOTS-C if:

• Your goal is metabolic support, not muscle growth
• You are trying to improve or protect insulin sensitivity, especially as an older athlete with declining endogenous MOTS-C
• You accept that the human efficacy evidence is thin and you will track HOMA-IR to see if it works for you

On running them together:

• The pairing is mechanistically logical: MOTS-C's AMPK activation opposes MK-677's GH-driven insulin resistance
• But no human trial has tested co-administration, and there is no proof MOTS-C reverses MK-677's metabolic cost
• Do not run MK-677 more aggressively on the assumption MOTS-C cancels it out. If managing MK-677's glucose effect is the goal, dose reduction, metformin, or switching to a pulsatile option like tesamorelin are better-evidenced choices